Search research articles
Contact Us
Filters
Showing results (181-190 of 282) with videos related to
Page
of 29
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
Urology
|
December 29, 2020
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary
Martin R Hofmann, Maha Hussain, Scott M Dehm, et al.
Nature Communications
|
December 11, 2024
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Todd P Knutson, Bin Luo, Anna Kobilka, et al.
BMJ Open
|
June 16, 2023
Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials
Hwanhee Hong, Anne Friedland, Mengyi Hu, et al.
Prostate Cancer and Prostatic Diseases
|
March 16, 2022
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer
Landon C Brown, Susan Halabi, Jason A Somarelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
Himisha Beltran, Alexander W Wyatt, Edmund C Chedgy, et al.
European Urology Focus
|
February 19, 2026
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)
Susan Halabi, Bin Luo, Chenxi Yu, et al.
Journal of the National Cancer Institute
|
September 7, 2023
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial
Takayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, et al.
JCO Precision Oncology
|
February 1, 2022
Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Tareq Al Baghdadi, Susan Halabi, Elizabeth Garrett-Mayer, et al.
Page
of 29
Search research articles
Search
Showing results (181-190 of 282) with videos related to
Sort By:
Page
of 29
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
Urology
|
December 29, 2020
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary
Martin R Hofmann, Maha Hussain, Scott M Dehm, et al.
Nature Communications
|
December 11, 2024
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Todd P Knutson, Bin Luo, Anna Kobilka, et al.
BMJ Open
|
June 16, 2023
Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials
Hwanhee Hong, Anne Friedland, Mengyi Hu, et al.
Prostate Cancer and Prostatic Diseases
|
March 16, 2022
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer
Landon C Brown, Susan Halabi, Jason A Somarelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
Himisha Beltran, Alexander W Wyatt, Edmund C Chedgy, et al.
European Urology Focus
|
February 19, 2026
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)
Susan Halabi, Bin Luo, Chenxi Yu, et al.
Journal of the National Cancer Institute
|
September 7, 2023
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial
Takayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, et al.
JCO Precision Oncology
|
February 1, 2022
Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Tareq Al Baghdadi, Susan Halabi, Elizabeth Garrett-Mayer, et al.
Page
of 29